Farringdon Capital, Ltd. Alkermes Plc. Transaction History
Farringdon Capital, Ltd.
- $242 Billion
- Q4 2024
A detailed history of Farringdon Capital, Ltd. transactions in Alkermes Plc. stock. As of the latest transaction made, Farringdon Capital, Ltd. holds 7,084 shares of ALKS stock, worth $254,244. This represents 0.08% of its overall portfolio holdings.
Number of Shares
7,084Holding current value
$254,244% of portfolio
0.08%Shares
1 transactions
Others Institutions Holding ALKS
# of Institutions
372Shares Held
175MCall Options Held
140KPut Options Held
143K-
Black Rock Inc. New York, NY29.1MShares$1.04 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.5MShares$664 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD12.3MShares$440 Million0.04% of portfolio
-
State Street Corp Boston, MA8.81MShares$316 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY7.56MShares$271 Million3.55% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $5.9B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...